In this outpatient memory clinic-based study, we examined the performance of two promising biomarkers of neurodegeneration and neuroinflammation, NfL, and GFAP, for the diagnostic work-up of patients along the continuum of AD-related cognitive decline. This evidence concerns the gene GFAP and Alzheimer disease.